Fate Therapeutics, Inc.

NasdaqGM:FATE Stock Report

Market Cap: US$835.2m

Fate Therapeutics Future Growth

Future criteria checks 0/6

Fate Therapeutics's earnings are forecast to decline at 7.7% per annum while its annual revenue is expected to grow at 3% per year. EPS is expected to grow by 0.4% per annum. Return on equity is forecast to be -70.2% in 3 years.

Key information

-7.7%

Earnings growth rate

0.4%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate3.0%
Future return on equity-70.2%
Analyst coverage

Good

Last updated19 Mar 2024

Recent future growth updates

Recent updates

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Feb 16
Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Jan 26

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Dec 19
Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Sep 08
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Jun 07
Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

May 08
Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Apr 17
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Sep 22
Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Aug 30

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Jul 28

Fate Therapeutics names Brian Powl as chief commercial officer

Jun 30

Fate: Possible Speedy FDA Approval Process With RMAT Designation

Jun 03

We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Jun 02
We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Fate Therapeutics: Slowly Getting To An Attractive Position

Feb 21

We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Feb 01
We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Fate Therapeutics: Data Playing Catchup With Valuation

Dec 06

Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans

Oct 16
Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans

Fate Therapeutics: We Will Wait For Durability Data

Sep 16

Earnings and Revenue Growth Forecasts

NasdaqGM:FATE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266-252-150-575
12/31/20255-211-163-14714
12/31/20245-195-139-15517
12/31/202364-161-138-132N/A
9/30/2023106-173-184-171N/A
6/30/2023119-212-209-188N/A
3/31/2023137-235-241-212N/A
12/31/202296-282-284-248N/A
9/30/202269-294-290-243N/A
6/30/202268-254-275-221N/A
3/31/202263-233-257-200N/A
12/31/202156-212-214-163N/A
9/30/202155-197-148-113N/A
6/30/202148-212-131-111N/A
3/31/202140-185-47-40N/A
12/31/202031-173-44-39N/A
9/30/202018-149-49-44N/A
6/30/202013-117-39-33N/A
3/31/202011-112-99-92N/A
12/31/201911-98-91-83N/A
9/30/201910-86-75-69N/A
6/30/20198-76-58-52N/A
3/31/20196-72-47-44N/A
12/31/20185-67-41-39N/A
9/30/20184-63-40-38N/A
6/30/20184-57-46-45N/A
3/31/20184-47-44-42N/A
12/31/20174-43-39-37N/A
9/30/20174-38N/A-34N/A
6/30/20174-36N/A-31N/A
3/31/20174-35N/A-30N/A
12/31/20164-33N/A-30N/A
9/30/20164-33N/A-29N/A
6/30/20164-31N/A-29N/A
3/31/20164-30N/A-19N/A
12/31/20152-30N/A-18N/A
9/30/20151-29N/A-18N/A
6/30/20150-28N/A-16N/A
3/31/2015N/A-27N/A-24N/A
12/31/2014N/A-26N/A-22N/A
9/30/2014N/A-25N/A-21N/A
6/30/20140-25N/A-19N/A
3/31/20140-24N/A-17N/A
12/31/20131-21N/A-15N/A
9/30/20132-19N/A-14N/A
6/30/20132-17N/A-13N/A
3/31/20133-15N/A-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FATE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FATE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FATE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FATE's revenue (3% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: FATE's revenue (3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FATE is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.